Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Authors:
Open Access
- 15 November 2022
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9443-9445